In accordance with previous studies performed in different tumors, we found that MUC1 knockdown decreased cell migration and viability and improved cisplatin susceptibility, suggesting that this protein can be involved in de novo chemotherapy resistance in ccRCC. The gene discussed is MUC1; the disease is nonpapillary renal cell carcinoma.